Sanofi-Aventis Suspends Phase III Acomplia Trial in Japan
This article was originally published in PharmAsia News
Sanofi Aventis announced Nov. 6 that the company decided to halt all clinical trials for obesity drug Acomplia (rimonabant) in compliance with European Medicines Agency's recommendation. The company has three ongoing Phase III trials in Europe and one in Japan for rimonabant. The company suspended marketing the drug in 18 European countries Oct. 23 due to the EMEA's recommendation. The agency cited mental disorder risks. Rimonabant is currently sold in 14 countries outside Europe. (Click here for more - Japanese language
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.